trending Market Intelligence /marketintelligence/en/news-insights/trending/MOaj_SVhzyFRPjw_crEBNg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Aimmune allergy drug improves tolerability of peanuts in European phase 3 study

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Aimmune allergy drug improves tolerability of peanuts in European phase 3 study

An Aimmune Therapeutics Inc. allergy medication improved the tolerability of peanuts in children following nine months of treatment, meeting the main goal of a phase 3 European clinical trial.

The drug, AR101, is intended to reduce the risk of anaphylaxis — a potentially life-threatening allergic reaction that includes skin rash and difficulty in breathing — due to accidental exposure to peanuts.

Aimmune enrolled 175 children and adolescents ages 4 to 17 in the phase 3 trial known as Artemis. The participants took increasing doses of the drug during the first six months followed by a daily dose of 300 milligrams.

The proportion of patients in the treatment arm of the trial who saw their tolerability of peanut protein grow from 10 milligrams to 1,000 milligrams was significantly higher compared to the placebo group. No cases of anaphylaxis were observed during the trial.

Based on the results of this late-stage study, the Brisbane, Calif.-based biotechnology company plans to submit a marketing application for AR101 to the European Medicines Agency in midyear.

The U.S. Food and Drug Administration recently accepted Aimmune's biologics license application for the peanut allergy drug. According to Aimmune, the FDA's review of AR101 could take until January 2020.

The results from Artemis are similar to a previous phase 3 study in which 50.3% of the AR101-treated patients were able to tolerate 1,000 milligrams of peanut protein.